Stock Track | Bionano Genomics Plummets 8.13% Following Q3 Earnings Release and Revenue Outlook

Stock Track11-14

Shares of Bionano Genomics (BNGO) plunged 8.13% in intraday trading following the release of the company's third-quarter financial results and full-year revenue outlook. The significant drop suggests that investors were disappointed with the company's performance and future prospects.

Bionano Genomics reported Q3 revenue of $7.4 million, with a gross margin of 46%. However, the company's operating expenses for the quarter stood at $11.9 million, with adjusted operating expenses at $9.7 million. These figures indicate that the company is still operating at a loss, which may have contributed to the negative market reaction.

Adding to investor concerns, Bionano Genomics provided a full-year revenue outlook of $26-30 million. This guidance might have fallen short of market expectations, potentially signaling slower growth or challenges in the company's business model. The combination of current financial results and future projections appears to have shaken investor confidence, leading to the sharp decline in stock price.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1134843547?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 05:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134843547","market":"sg","top_or_hot":-1,"title":"Stock Track | Bionano Genomics Plummets 8.13% Following Q3 Earnings Release and Revenue Outlook","media":"Stock Track","content":"<p>Shares of Bionano Genomics (BNGO) plunged 8.13% in intraday trading following the release of the company's third-quarter financial results and full-year revenue outlook. The significant drop suggests that investors were disappointed with the company's performance and future prospects.</p>\n\n<p>Bionano Genomics reported Q3 revenue of $7.4 million, with a gross margin of 46%. However, the company's operating expenses for the quarter stood at $11.9 million, with adjusted operating expenses at $9.7 million. These figures indicate that the company is still operating at a loss, which may have contributed to the negative market reaction.</p>\n\n<p>Adding to investor concerns, Bionano Genomics provided a full-year revenue outlook of $26-30 million. This guidance might have fallen short of market expectations, potentially signaling slower growth or challenges in the company's business model. The combination of current financial results and future projections appears to have shaken investor confidence, leading to the sharp decline in stock price.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Bionano Genomics Plummets 8.13% Following Q3 Earnings Release and Revenue Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Bionano Genomics Plummets 8.13% Following Q3 Earnings Release and Revenue Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-14 05:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Bionano Genomics (BNGO) plunged 8.13% in intraday trading following the release of the company's third-quarter financial results and full-year revenue outlook. The significant drop suggests that investors were disappointed with the company's performance and future prospects.</p>\n\n<p>Bionano Genomics reported Q3 revenue of $7.4 million, with a gross margin of 46%. However, the company's operating expenses for the quarter stood at $11.9 million, with adjusted operating expenses at $9.7 million. These figures indicate that the company is still operating at a loss, which may have contributed to the negative market reaction.</p>\n\n<p>Adding to investor concerns, Bionano Genomics provided a full-year revenue outlook of $26-30 million. This guidance might have fallen short of market expectations, potentially signaling slower growth or challenges in the company's business model. The combination of current financial results and future projections appears to have shaken investor confidence, leading to the sharp decline in stock price.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNGO","symbol_name":"Bionano Genomics","start_time":0,"source_url":"","article_id":"1134843547","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134843547","pubTimestamp":1763067755,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Bionano Genomics (BNGO) plunged 8.13% in intraday trading following the release of the company's third-quarter financial results and full-year revenue outlook. The significant drop suggests...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNGO":"Bionano Genomics"},"translate_title":"个股追踪|Bionano Genomics在第三季度财报发布和营收展望后暴跌8.13%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNGO":1},"content_text":"Shares of Bionano Genomics (BNGO) plunged 8.13% in intraday trading following the release of the company's third-quarter financial results and full-year revenue outlook. The significant drop suggests that investors were disappointed with the company's performance and future prospects.\nBionano Genomics reported Q3 revenue of $7.4 million, with a gross margin of 46%. However, the company's operating expenses for the quarter stood at $11.9 million, with adjusted operating expenses at $9.7 million. These figures indicate that the company is still operating at a loss, which may have contributed to the negative market reaction.\nAdding to investor concerns, Bionano Genomics provided a full-year revenue outlook of $26-30 million. This guidance might have fallen short of market expectations, potentially signaling slower growth or challenges in the company's business model. The combination of current financial results and future projections appears to have shaken investor confidence, leading to the sharp decline in stock price.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1134843547","isCrawlerRequest":true}